{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Cancer", "query": { "condition": "Locally Advanced Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2280, "total_pages": 228, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T16:39:09.351Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00329797", "title": "Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteoporosis", "Prostate Cancer" ], "interventions": [ { "name": "Calcium", "type": "DIETARY_SUPPLEMENT" }, { "name": "Zoledronic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "LHRH", "type": "DRUG" }, { "name": "Vitamin D", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "RADIATION", "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 109, "start_date": "2006-03", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 80, "location_summary": "Chico, California • Los Angeles, California • Pomona, California + 66 more", "locations": [ { "city": "Chico", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pomona", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00329797" }, { "nct_id": "NCT05668988", "title": "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "sunvozertinib", "type": "DRUG" }, { "name": "Pemetrexed+carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dizal Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2022-12-13", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 14, "location_summary": "Glendale, California • Vallejo, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Margate", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05668988" }, { "nct_id": "NCT03991741", "title": "Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Melanoma", "Locally Advanced Refractory/Recurrent Melanoma", "Metastatic Head and Neck Cancer", "Locally Advanced Refractory/Recurrent Head and Neck Cancer" ], "interventions": [ { "name": "Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" }, { "name": "High-Dose Interleukin 2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gregory Daniels", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-10-07", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03991741" }, { "nct_id": "NCT06116136", "title": "A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "MSI-H/dMMR Gastroesophageal-junction Cancer", "MSI-H/dMMR Gastric Cancer" ], "interventions": [ { "name": "S095029", "type": "DRUG" }, { "name": "pembrolizumab 200 mg (KEYTRUDA ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Servier Bio-Innovation LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-08-31", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 3, "location_summary": "Ocala, Florida • Noblesville, Indiana • Houston, Texas", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116136" }, { "nct_id": "NCT00225173", "title": "Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2001-10", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2014-08-27", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225173" }, { "nct_id": "NCT04736173", "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Nonsquamous Non Small Cell Lung Cancer", "Squamous Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2021-02-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 3, "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Kingwood", "state": "Texas" }, { "city": "Blacksburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736173" }, { "nct_id": "NCT01526473", "title": "A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2+ Cancer" ], "interventions": [ { "name": "AVX901", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Kim Lyerly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2012-02", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01526473" }, { "nct_id": "NCT00468169", "title": "Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Twice-daily radiation", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Accelerated fraction radiotherapy with concomitant boost", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2006-07", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2019-10-09", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00468169" }, { "nct_id": "NCT00492830", "title": "Phase 1, Open-label, Dose Escalation Study of TRC093, in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "TRC093 recombinant humanized IgG1k monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2007-06", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-02-05", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492830" }, { "nct_id": "NCT03899636", "title": "A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Pancreatic Cancer" ], "interventions": [ { "name": "Modified FOLFIRINOX Regimen", "type": "DRUG" }, { "name": "NanoKnife System", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Angiodynamics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 528, "start_date": "2021-02-23", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-06-25T16:39:09.351Z", "location_count": 6, "location_summary": "Miami, Florida • Tampa, Florida • Arlington Heights, Illinois + 3 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Easton", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03899636" } ] }